Need professional-grade analysis? Visit stockanalysis.com
$3.50T
N/A
917
N/A
SK Bioscience Co Ltd (302440) trades on KO in KRW. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at KRW46600.00, up 4.37% from the previous close.
Over the past year, 302440 has traded between a low of KRW38650.00 and a high of KRW60100.00. The stock has gained 20.6% over this period. It is currently 22.5% below its 52-week high.
SK Bioscience Co Ltd has a market capitalization of $3.50T.
SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea. SK bioscience Co.,Ltd. is a subsidiary of SK Chemicals Co.,Ltd.
Side-by-side comparison against top Healthcare peers.